Regenera to list in early June
Wednesday, 19 May, 2004
The CEO of Perth-based biotech Regenera, Tony Fitzgerald, said today that he expected the company’s offer to close next week, oversubscribed, ready for a June listing.
Regenra plans to raise AUD$8 million to develop its therapy for age related macular degeneration AMD – a condition in which damage to the retina causes visual impairment. The therapy involves injecting a steroid, triamciolone acetomide, into the back of the eye every six months.
“We have had a very good response in a difficult market,” said Fitzgerald. He said there had been significant Australian investment and that a number of international opthamologists were also supporting the company.
Fitzgerald plans to gain both TGA approval and an international licence for Regenera's product, possibly as a co-therapy with another AMD treatment.
Why a gluten-free diet fails in some coeliac patients
Abnormal immune cells are driving ongoing intestinal inflammation that causes symptoms like...
Giving rotavirus vaccine at birth benefits gut bacteria
Babies who receive a RV3-BB rotavirus vaccine at birth appear to show higher levels of good...
TGA approves donanemab for treatment of early Alzheimer's
The TGA has approved the first amyloid-targeting therapy for people with Alzheimer's in...
